Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Target Tacrolimus Trough Achievement with Extended-Release Formulation in Kidney Transplant Recipients
ChiCTR2600125220Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney allograft rejection (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Tacrolimus whole blood trough concentration. Started May 2026; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on ChiCTR2600125220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125220.